Given that JNK1, the upstream molecule, is highly expressed (55%) in HCC42, our results which are in line with those from the previous study23, suggest the possibility on combined therapy with sorafenib and JNK1 inhibitor as a promising therapeutic perspective in HCC. The gene discussed is MAPK8; the disease is hepatocellular carcinoma.